UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Wave Life Sciences Ltd.
(Name of Issuer)
$0 Par Value Ordinary Share
(Title of Class of Securities)
Y95308105
(CUSIP Number)
January 23, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☒ | Rule 13d-1(c) |
| ☐ | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond to the collection of information
contained in this form are not
required to respond unless the form displays a currently valid OMB control number.
| CUSIP No. Y95308105 | |
|
1. Names of Reporting Persons.
GSK plc | |
|
2. Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
| |
| 3. SEC Use Only | |
| 4. Citizenship or Place of Organization England and Wales | |
| Number of Shares Beneficially Owned by Each Reporting Person With: |
5. Sole Voting Power 10,683,761 (1) |
| 6. Shared Voting Power 0 | |
| 7. Sole Dispositive Power 10,683,761 (1) | |
| 8. Shared Dispositive Power 0 | |
|
9. Aggregate Amount Beneficially Owned by Each Reporting Person 10,683,761 (1) | |
| 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐ | |
| 11. Percent of Class Represented by Amount in Row (9) 10.95% (2) | |
| 12. Type of Reporting Person CO | |
(1) Represents shares of the Issuer’s $0 Par Value Ordinary Shares (the “Ordinary Shares”) held of record by Glaxo Group Limited (“GGL”), a wholly-owned subsidiary of the Reporting Person.
(2) The percentage reported herein is based upon (i) 86,909,643 Ordinary Shares outstanding as of December 12, 2022, as reported in the Issuer’s Form 8-K furnished with the Securities and Exchange Commission (the “SEC”) on December 13, 2022, and (ii) 10,683,761 Ordinary Shares acquired directly by GGL.
ITEM 1.
| (a) | Name of Issuer: |
Wave Life Sciences Ltd. (the “Issuer”)
(b) Address of Issuer's Principal Executive Offices:
7 Straits View #12-00
Marina One, East Tower
Singapore 018936
ITEM 2.
| (a) | Name of Person Filing: |
GSK plc
| (b) | Address of Principal Business Office, or if None, Residence: |
980 Great West Road
Brentford
Middlesex
TW8 9GS
England
(c) Citizenship:
England and Wales
(d) Title of Class of Securities:
$0 Par Value Ordinary Shares (the “Ordinary Shares”)
(e) CUSIP Number:
Y95308105
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
Not Applicable
ITEM 4. OWNERSHIP.
The information in items 1 and 5 through 11 on the cover page of this Schedule 13G is hereby incorporated by reference.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Glaxo Group Limited* 10,683,761 10.95%
*Shares are held of record by Glaxo Group Limited, an indirect wholly-owned subsidiary of the Reporting Person.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not Applicable
ITEM 10. CERTIFICATIONS.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: January 30, 2023
| GSK plc | ||
| By: | /s/ Victoria A. Whyte | |
| Victoria A. Whyte | ||
| Authorized Signatory | ||